ScaleReady Partners with Sonoma Biotherapeutics for G-Rex Grant
In an exciting development within the biotechnology sector, ScaleReady has announced a collaboration with Sonoma Biotherapeutics along with Wilson Wolf Manufacturing and Bio-Techne Corporation. This partnership has resulted in a significant grant of $300,000 aimed at the advancement of gene-modified regulatory T cell (Treg) therapies that are critical for treating various autoimmune disorders.
Understanding the Impact of the G-Rex Grant
The awarded G-Rex Grant is instrumental for Sonoma Biotherapeutics as it transitions to a more efficient manufacturing process. This innovative effort will utilize the G-Rex platform, which is designed to enhance the production of regulatory T cells, moving beyond traditional flask-based technologies. Such advancements are not just technical progressions but fundamental shifts that could drastically improve patient outcomes for those suffering from debilitating conditions.
Expert Insights on Regulatory T Cells
John Wilson, CEO of Wilson Wolf and a co-inventor of the G-Rex technology, expressed enthusiasm about this grant, stating that regulatory T cells represent a promising avenue for treatment. The G-Rex Grant provides critical support for Sonoma Biotherapeutics, aligning with the mission to deliver revolutionary therapies to patients in need.
Streamlining the Manufacturing Process
This grant will facilitate SonomaBiotherapeutics's exploration of advanced optimization strategies for their Treg platform. A key goal is to create a modular and scalable manufacturing approach, which is vital for meeting the demands of clinical investigations. By incorporating closed systems with G-Rex devices and ProPak™ GMP Cytokines, this initiative signifies a progressive leap in biomanufacturing techniques.
ScaleReady's Broader Commitments
ScaleReady's commitment to enhancing cell and gene-modified therapy (CGT) development is noteworthy, with over $40 million already allocated to similar grants. These funds are aimed at pushing the boundaries of CGT manufacturing forward, assisting various entities in streamlining their development processes. Awardees of the G-Rex Grant also benefit from specialized support provided through ScaleReady's extensive network of partners.
A New Era of Collaboration
As part of its innovative approach, ScaleReady is proud to introduce the LEAN Cell & Gene™ program. This initiative, developed in collaboration with Hanson Wade, is set to create a platform for CGT entities to come together, share best practices, and learn how to optimize their manufacturing processes. This event series is open to all in the sector, marking a comprehensive effort to enhance CGT manufacturing efficiency.
About ScaleReady
ScaleReady is redefining the landscape of cell and gene-modified cell therapy through its G-Rex-centric manufacturing platform. This platform has gained recognition for its practicality, scalability, and affordability, making it the preferred choice for those in the CGT field.
Bio-Techne Corporation and Supportive Partnerships
Bio-Techne Corporation (NASDAQ: TECH) complements this ecosystem with its cutting-edge tools and reagents tailored for CGT applications. The combined expertise of these companies is vital in fostering a more accessible and effective gene therapy landscape.
Frequently Asked Questions
What is the purpose of the G-Rex Grant?
The G-Rex Grant aims to support the development of gene-modified Treg therapies for treating autoimmune disorders.
Who are the key collaborators for this grant?
The grant collaboration includes ScaleReady, Sonoma Biotherapeutics, Wilson Wolf Manufacturing, and Bio-Techne Corporation.
How does the G-Rex platform enhance manufacturing?
The G-Rex platform simplifies the manufacturing process, allowing for scalable and efficient production compared to traditional methods.
What can participants expect from the LEAN Cell & Gene™ program?
Participants will learn how to optimize operations, reduce waste, and ultimately improve product quality in CGT manufacturing.
How does ScaleReady support its grant recipients?
Grant recipients gain access to tools, technologies, and expertise in areas like cGMP manufacturing and regulatory affairs to facilitate their development processes.
